Business / Finance

RSS

XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).

13 Oct 2015

Gensignia gets CLIA certification to establish clinical laboratory in San Diego

Gensignia Life Sciences, Inc. (Gensignia) announced today that it received certification under the Clinical Laboratory Improvement Amendments (CLIA).

13 Oct 2015

MiMedx posts record revenue of $49M in Q3 2014

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today its record revenue results for the third quarter of 2015, its guidance for the fourth quarter of 2015, and that the Company has secured a $50 million Senior Secured Credit Facility.

13 Oct 2015

Nobel Laureate Harold Varmus, MD to delivery anniversary discourse at The New York Academy of Medicine November 5

Harold Varmus, MD, co-recipient of the 1989 Nobel Prize in Medicine and Lewis Thomas University Professor of Medicine at Meyer Cancer Center of Weill Cornell Medical College, will deliver the 168th Anniversary Discourse at The New York Academy of Medicine. The event will take place on Thursday, November 5, 2015 at 6:00 p.m. at the Academy (1216 Fifth Avenue at 103rd Street) and is free and open to the public with registration.

13 Oct 2015

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

Astute Medical, Inc. today announced the signing of an agreement with Shanghai Fosun Long March Medicine Science Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., for distribution of Astute's NephroCheck Test on the Astute140 Meter in China. In addition to its planned launch of the NephroCheck Test in China, FOSUNPHARMA invested $20 million in Astute.

12 Oct 2015

MiNDERA closes $1 million Seed financing round

MiNDERA Corp., a leader in non-invasive molecular diagnostics for dermatology and skin-related cancers, announced today the close of its $1 million Seed financing round. Scientific Health Development and other individual investors are among MiNDERA's new investors. This financing round will enable MINDERA to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.

12 Oct 2015

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Eli Lilly and Company and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia.

11 Oct 2015

Roche to acquire biotechnology company, Adheron Therapeutics

Adheron Therapeutics, a privately held biotechnology company based in Berkeley, California, United States, announced today that it has agreed to be acquired by Roche.

9 Oct 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire iForce.

9 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

To honor six cancer survivors featured in its newest international ad campaign, NanoString Technologies, Inc. will donate $6,000 to the American Cancer Society. The “Dear Cancer Researcher” participants courageously shared their personal stories of triumph to help the biotechnology company launch its newest product, nCounter SPRINT™ Profiler, a system that gives researchers the tools and opportunity to think beyond current everyday practice.

From NanoString Technologies 9 Oct 2015

Avita Medical gains two CE marks to complete skin healing portfolio

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.

9 Oct 2015

CRF Health launches new website and industry-first eCOA resource hub

CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today launched its new website, www.crfhealth.com, which includes an industry-first online eCOA resource hub. The multimedia platform provides a wide range of webinars, eBooks, articles and videos covering the effective implementation, management and scaling of eCOA technology for global clinical trials.

9 Oct 2015

Boston Scientific closes additional financing with MValve Technologies

Boston Scientific Corporation today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS Valve, creating a unique mitral regurgitation (MR) treatment solution.

8 Oct 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.

8 Oct 2015

Blackstone enters into definitive agreement to acquire BioMed Realty for $8 billion

BioMed Realty Trust, Inc. today announced that it has entered into a definitive agreement with affiliates of Blackstone Real Estate Partners VIII, under which Blackstone will acquire all outstanding shares of common stock of BioMed Realty for $23.75 per share in an all-cash transaction valued at $8 billion.

8 Oct 2015

Claritas Genomics announces launch of Claritas Clinical Exome, novel diagnostic test

Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient’s clinical whole exome within 4 weeks, compared to the industry standard of 12 weeks or more. Patients with rare disease typically seek a diagnosis for 8-12 years, receiving 3-5 separate tests at a high cost.

7 Oct 2015

Invitae announces dramatic expansion of genetic testing menu

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin releasing the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric and other rare disorders.

7 Oct 2015

New white paper on active-ULD performance from CSafe Global

CSafe Global, the world's largest producer of actively controlled mobile refrigeration units for biopharmaceutical and healthcare applications, has released a white paper highlighting the problems and risk associated with using poorly maintained container stock.

7 Oct 2015

Cell Therapy Catapult launches Cell History File

The Cell Therapy Catapult, the organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the availability of the Cell History File (CHF) template document. The Cell History File template has been developed in conjunction with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the Human Tissue Authority (HTA) and other cell therapy developers and manufacturers from academia and industry.

7 Oct 2015

Business / Finance

XTL signs agreement with Yeda to amend development milestones for lupus treatment

Gensignia gets CLIA certification to establish clinical laboratory in San Diego

MiMedx posts record revenue of $49M in Q3 2014

Nobel Laureate Harold Varmus, MD to delivery anniversary discourse at The New York Academy of Medicine November 5

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

MiNDERA closes $1 million Seed financing round

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Roche to acquire biotechnology company, Adheron Therapeutics

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

Avita Medical gains two CE marks to complete skin healing portfolio

CRF Health launches new website and industry-first eCOA resource hub

Boston Scientific closes additional financing with MValve Technologies

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Blackstone enters into definitive agreement to acquire BioMed Realty for $8 billion

Claritas Genomics announces launch of Claritas Clinical Exome, novel diagnostic test

Invitae announces dramatic expansion of genetic testing menu

New white paper on active-ULD performance from CSafe Global

Cell Therapy Catapult launches Cell History File

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Latest News